Fatal myeloproliferation, induced in mice by TEL/PDGFR expression, depends on PDGFR tyrosines 579/581

Michael H. Tomasson, David W. Sternberg, Ifor R. Williams, Martin Carroll, Danielle Cain, Jon C. Aster, Robert L. Ilaria, Jr., Richard A. Van Etten, and D. Gary Gilliland

1Department of Medicine, Brigham and Women’s Hospital, Harvard Institutes of Medicine, Boston, Massachusetts 02115, USA
2Department of Pathology, Emory University, Atlanta, Georgia 30322, USA
3Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
4The Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75235, USA
5Department of Pathology, Brigham and Women’s Hospital,
6Center for Blood Research, and
7Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts 02115, USA

Address correspondence to: D. Gary Gilliland, Harvard Institutes of Medicine, 4 Blackfan Circle, Room 421, Boston, Massachusetts 02115, USA. Phone: (617) 525-5525; Fax: (617) 525-5530; E-mail: gilliland@calvin.bwh.harvard.edu.

Received for publication November 11, 1999, and accepted in revised form December 30, 1999.

The t(5;12)(q33;p13) translocation associated with chronic myelomonocytic leukemia (CMML) generates a TEL/PDGFR fusion gene. Here, we used a murine bone marrow transplant (BMT) assay to test the transforming properties of TEL/PDGFR in vivo. TEL/PDGFR, introduced into whole bone marrow by retroviral transduction, caused a rapidly fatal myeloproliferative disease that closely recapitulated human CMML. TEL/PDGFR transplanted mice developed leukocytosis with Gr-1+ granulocytes, splenomegaly, evidence of extramedullary hematopoiesis, and bone marrow fibrosis, but no lymphoproliferative disease. We assayed mutant forms of the TEL/PDGFR fusion protein — including 8 tyrosine to phenylalanine substitutions at phosphorylated PDGFR sites to which various SH2 domain-containing signaling intermediates bind — for ability to transform hematopoietic cells. All of the phenylalanine (F-) mutants tested conferred IL-3-independence to a cultured murine hematopoietic cell line, but, in the BMT assay, different F-mutants displayed distinct transforming properties. In transplanted animals, tyrosines 579/581 proved critical for the development of myeloproliferative phenotype. F-mutants with these residues mutated showed no sign of myeloproliferation but instead developed T-cell lymphomas. In summary, TEL/PDGFR is necessary and sufficient to induce a myeloproliferative disease in a murine BMT model, and PDGFR residues Y579/581 are required for this phenotype.


Introduction
TEL/PDGFR is a fusion protein that is expressed as a consequence of the t(5;12) (q33;p13) chromosomal translocation in patients with chronic myelomonocytic leukemia (CMML) (1), a disease characterized by splenomegaly, abnormal myelopoiesis, myelofibrosis, and a predisposition to acute myeloid leukemia (AML) (2). As a result of the t(5;12), the NH2-terminal ligand-binding domain of the receptor tyrosine kinase PDGFR is replaced by the NH2-terminus of the transcription factor TEL, which contains the self-association domain, pointed (PNT; Figure 1a) (1). TEL/PDGFR forms oligomers mediated by the PNT domain and is a constitutively active tyrosine kinase (3). The ability of TEL/PDGFR to confer factor independence to Ba/F3 cells is dependent on the PNT domain of TEL and on the kinase activity of the PDGFR portion of the fusion (3). TEL/PDGFR is one of a growing list of chimeric oncoproteins that are dysregulated protein tyrosine kinases. The native PDGFR is a receptor tyrosine kinase, and ligand binding to PDGFR results in dimerization and autophosphorylation (4, 5). Phosphotyrosine residues of the activated receptor bind to specific SH2 domain proteins including SRC, PI3 kinase (PI3K), PLCγ, GRB2, SHP-2, and STAT5 that couple the receptor to downstream signal transduction pathways (5). Tyrosine to phenylalanine mutants of PDGFR that are incapable of binding specific signaling molecules have been used to demonstrate the roles of specific signal transduction pathways after activation by PDGF. In this way, it has been determined that either PI3K or PLCγ is required to stimulate mitogenesis in HepG2 cells (6).

Here we report that the TEL/PDGFR fusion gene is necessary and sufficient to cause a myeloproliferative disease in a murine bone marrow transplant (BMT) assay that closely resembles the human disease CMML and is characterized by hepatosplenomegaly, extramedullary...
hematopoiesis, myelofibrosis, and a neutrophilic leukocytosis. Furthermore, we have constructed a series of tyrosine to phenylalanine mutants of TEL/PDGFβR to examine the role of specific signal transduction pathways in transformation by TEL/PDGFβR and assessed the effects of these mutations on the development of CMML in the BMT assay.

Methods

Plasmid constructs. The 2.4-kb TEL/PDGFβR cDNA was subcloned into the multicloning site of the MSCV-neoEB retroviral vector containing a modified murine Moloney leukemia virus LTR and a neomycin resistance cassette (murine stem cell virus [MSCV], kindly provided by R. Hawley, Red Cross, Rockville, Maryland, USA) (7). TEL/PDGFβR tyrosine to phenylalanine mutants were generated by subcloning F2, F5, and F7 wild-type PDGFβR mutants (provided by A. Kaslauskas, Boston, Massachusetts, USA) into the TEL/PDGFβR background. Vectors expressing TEL/PDGFβR and related mutants cotranscriptionally with green fluorescent protein (GFP) using an internal ribosomal entry site (IRES) expression cassette were created by subcloning TEL/PDGFBβR and mutants into the MSCV2.1RESGFP retroviral vector (provided by W. Pear, University of Pennsylvania, Philadelphia, Pennsylvania, USA).

Production of retrovirus and determination of viral titers. TEL/PDGFβR and related MSCV retroviral constructs were used to make replication-incompetent retroviral supernatant by transient transfection of 293T cells. Bone marrow cells from normal mice pretreated with 5-fluorouracil was incubated with high-titer retroviral supernatant and intravenously injected into lethally irradiated syngeneic mice. The TEL/PDGFβR cDNA described by Golub et al. (1) was cloned into the MSCVneoEB retroviral vector (6) to create MSCVneoT/P. The plasmid containing packaging sequences, pK6.1MCV.ecopac.UTd (Ecopac), was obtained from M. Finer (Cell Genesys, Redwood City, California, USA). 293T cells were transfected with MSCVneoT/P and Ecopac using the SuperPhect (Pharmacia, Uppsala, Sweden) calcium phosphate method per the manufacturer’s instructions. All supernatants were collected 48 hours after transfection and passed through a 0.45-μm filter before freezing at –80°C. Supernatant was tested by infecting 3T3 cells, and viral titer was estimated by quantitating neomycin-resistant colonies as described (8).

Retrovirally mediated gene transfer and BMT. On day –8 of each BMT procedure, 6- to 8-week-old BALB/c mice were pretreated with 150 mg/kg of 5-fluorouracil administered by intraperitoneal injection. On day –2, bone marrow was harvested from these donor mice and red blood cells were lysed by incubation for 5 minutes on ice with an ammonium chloride lysis solution (150 mM NH₄Cl, 10 mM KHCO₃, 0.1 mM EDTA [pH 7.4]). The remaining mononuclear marrow cells were then resuspended in RPMI medium containing 1 mL viral supernatant, 20% FBS, 6 ng/mL recombinant mouse IL-3 (Genzyme, Cambridge, Massachusetts, USA), 100 ng/mL recombinant mouse stem cell factor (Genzyme), and 10 ng/mL recombinant mouse IL-6 (PeproTech, Rocky Hill, New Jersey, USA). The cells were plated onto a 10-cm tissue culture plate treated with the fibronectin fragment CH-296 (RetroNectin PanVera, Madison, Wisconsin, USA) per the manufacturer’s instructions. At 24 hours, an additional 1 mL of viral supernatant was added; cells were recovered by gentle scraping at 48 hours after plating, counted, and resuspended in Hanks’ buffered saline. A total of 144 mice were transplanted in 3 separate experiments that all yielded equivalent results. Sublethally irradiated syngeneic mice used for secondary transplants were subjected to a single dose of 450 cGy.

Assessment of mice. Animals were monitored 3 times
per week for the development of disease by inspection and palpation of the spleen and femoral lymph nodes. Peripheral blood was obtained by retroorbital phlebotomy using heparinized Natelson blood collecting tubes (Fisher Scientific, Pittsburgh, Pennsylvania, USA) after adequate methoxyfluorane (Mallinckrodt Veterinary, Mundelein, Illinois, USA) anesthesia. Mice with disease evidenced by abnormal white blood cell counts, splenomegaly, lymphadenopathy, or shortness of breath were sacrificed by CO₂ asphyxiation followed by cervical dislocation. Bone marrow cells were isolated by flushing femurs and tibias with PBS. Single-cell suspensions were prepared by passing spleen and lymph node tumor tissue through nylon mesh (Falcon, Lincoln Park, New Jersey, USA) wetted with PBS.

Expression analysis. Single-cell suspensions of tissues were prepared as just described. Total cellular RNA was isolated by resuspending 10³ cells in 1 mL of TRIzol (Life Technologies, Gaithersburg, Maryland, USA) and processing according to the manufacturer’s instructions. Total RNA (4 µg) from each sample was reverse transcribed using AMV RT (Life Technologies) for 1 hour at 42°C. To assess TEL/PDGFBR message in transplanted mice, 1 mL of cDNA solution was subjected to 40 cycles of PCR (94°C for 60 seconds, 53°C for 60 seconds, and 72°C for 60 seconds) using primers spanning the translocation breakpoint: TEL Bam-196, 5’-GCG GAT CCC AAT TTA CTG GAG CAG-3’ and PDGF-1979R 5’-GGG TCC CAG ACC AAG CTG GT-3’. Wild-type murine TEL message was used as a cDNA control subjecting the same cDNA solutions to 40 cycles of PCR using primers MTEL-1184, 5’-CAG CCC GGC ACC ACT AC-3’ and MTEL-1487R, 5’-CAG CCA TTT CTG GGT CG-3’.

Ba/F3 cell growth rates. Polyclonal Ba/F3 cell lines stably expressing TEL/PDGFBR were made by retroviral infection using 1 x 10⁶ cells, polybrene (American Bioanalytical, Natick, Massachusetts, USA), and supernatants prepared as already described here. Cells were selected in RPMI media containing 10% FBS, 1 ng/mL IL-3, and 1 mg/mL G418 (Sigma Chemical Co., St. Louis, Missouri, USA) for 7 days. Expression of TEL/PDGFBR and related mutants was confirmed by Western blot analysis using anti-tail PDGFBR antibody (PharMingen, San Diego, California, USA). Cells containing TEL/PDGFBR and related mutants were washed twice in media without IL-3 and allowed to grow to confluence. Cells containing vector alone and kinase-inactive TEL/PDGFBR were maintained in media containing IL-3. Cells were then plated at a concentration of 10⁴ per mL, and cells excluding Trypan blue (Sigma Chemical Co.) were counted daily for 1 week.

Proviral integration and T-cell receptor rearrangements. Genomic DNA was isolated from assorted tissues as described elsewhere (9). A total of 10 µg of each genomic DNA sample was digested with either XhoI (cuts twice in provirus) or EcoRI (cuts once) and subjected to agarose gel electrophoresis and transferred to nylon membranes (Hybond N⁺; Amersham, Arlington Heights, Illinois, USA) using alkaline transfer as described previously (10). Provirus was detected by Southern blotting using a 760-bp Eagl-BamHI fragment of the neomycin gene as a probe random labeled using 3³P³ dCTP (Boehringer Mannheim, Indianapolis, Indiana, USA). Hybridization was performed at 65°C for 16 hours, and membranes were washed with...
2 x SSC, 0.1% SDS, for 20 minutes at room temperature and with 1 x SSC, 0.1% SDS, at 65°C for 20 minutes and were exposed to photographic film (BioMax; Eastman Kodak, Rochester, New York, USA) at -80°C overnight. T-cell receptor β (TCR-β) chain gene rearrangements were detected using a 2-kb EcoRI fragment of Jβ2B plasmid (provided by B. Rich, Brigham and Women’s Hospital, Boston, Massachusetts, USA), 10 μg of genomic tumor DNA digested with HindIII, and an identical Southern blot protocol.

**Histology.** Murine tissues were fixed for 24 hours in 10% neutral buffered formalin and embedded in paraffin. Femurs were subjected to an additional decalcification step in RDO (Apex Engineering Products, Plainfield, Illinois, USA) for 4 hours before processing. Sections (3 μm) were deparaffinized and stained with hematoxylin and eosin (H&E).

**Flow cytometry.** Spleen cell suspensions were processed for flow cytometry as described previously (11). Antibodies used in the current analysis were biotin conjugates of anti-Gr-1 and anti-CD3 (PharMingen), phycoerythrin conjugates of anti-B220, anti-Thy-1.2, and anti-CD8α (PharMingen), and allophycocyanin-conjugated anti-CD4 (Caltag, South San Francisco, California, USA). Binding of the biotinylated primary antibodies to cells was detected using streptavidin labeled with allophycocyanin (Caltag). Acquisition and data analysis were performed on a FACStar running CellQuest 3.1 software (Becton Dickinson Immunocytometry Systems, San Jose, California, USA).

**Results**

**TEL/PDGFβR causes a fatal myeloproliferative syndrome in mice.** The in vivo transforming properties of TEL/PDGFβR were tested in a murine BMT assay. Briefly, TEL/PDGFβR was introduced into primary bone marrow cells by retroviral transduction and transplanted into lethally irradiated syngeneic recipient mice. Controls included 2 nontransforming TEL/PDGFβR mutants, K634R and TELΔPNT/PDGFβR mutants (3). The K634R mutant contains a single amino acid substitution in the catalytic domain of the PDGFβR portion of the fusion that abrogates tyrosine kinase activity and transformation of Ba/F3 cells by TEL/PDGFβR. Deletion of the TEL-PNT domain prevents TEL/PDGFβR from forming activated oligomers, and this mutant is similarly unable to transform Ba/F3 cells to factor independence (3).

Fifty mice were transplanted with TEL/PDGFβR (39 mice), kinase-inactive K634R (6 mice), or ΔPNT mutants (controls, 5 mice) (Table 1). All (39/39; 100%) TEL/PDGFβR transplanted mice developed peripheral leukocytosis and splenomegaly and died within 65 days of transplantation (median survival = 31 days). Nine of these mice were transplanted with a TEL/PDGFβR retroviral construct containing, instead of a neomycin resistance cassette, a cassette allowing for expression of GFP from an IRES (Figure 1b). These mice developed an identical myeloproliferative disease with a similar latency (data not shown). In contrast, 0 of 11 (0%) mice transplanted with the kinase-inactive K634R TEL/PDGFβR mutant or the TELΔPNT/PDGFβR mutant developed disease, and they remain alive and free of disease at 1 year after transplant (Table 1). TEL/PDGFβR transplanted mice had peripheral blood leukocyte counts as high as 5.1 x 10^8 per mL (range: 4.9 x 10^7 to 5.1 x 10^8; normal: 2.0 x 10^8 to 12.0 x 10^8) consisting of myeloid lineage cells at all stages of maturation (Figure 2a), analogous to CMML in...
there was no evidence for proviral integration in lymph node or thymus (Figure 3c). Clonality of the abnormal cells was assessed using a restriction endonuclease (EcoRI) that cleaves once within the provirus. Each independent viral integration event thus yielded a unique band. The tumors in mice transplanted with TEL/PDGFBKR were oligo- or polyclonal, as evidenced by multiple bands in these lanes (Figure 3c).

Transplantability. Cells from diseased mice were transplanted into secondary recipients. Two experiments using $1 \times 10^6$ spleen cells (4 mice) or marrow cells (4 mice) from mice with TEL/PDGFBKR disease failed to cause disease in sublethally irradiated secondary recipients. In a third experiment, 8 lethally irradiated mice were injected with $5 \times 10^6$ spleen cells each, and 8 mice were injected with $1 \times 10^6$ bone marrow cells each. One of 8 mice from the spleen group developed a myeloproliferative disease with splenomegaly and peripheral leukocytosis (data not shown).

Signal transduction pathways associated with PDGFBR activation are not required for the transformation of Ba/F3 cells by TEL/PDGFBKR. The native PDGFBR requires specific tyrosine residues for signaling through distinct transduction pathways (5). To determine the tyrosine residues required for the development of the myeloproliferative phenotype, we analyzed a series of TEL/PDGFBKR mutants containing tyrosine to phenylalanine point mutations designed to abrogate the binding of specific SH2 adapter signaling molecules (Figure 4). Control experiments showed that these mutations had no effect on PDGFBR kinase activity in the context of the TEL/PDGFBKR fusion (D.W. Sternberg and D.G. Gilliland, unpublished observation). Ba/F3 cell lines expressing each of these mutants were generated and assessed for their ability to grow in the absence of IL-3. Each of the F-mutants conferred IL-3–independent growth to Ba/F3 cells (Figure 5). Furthermore, stable Ba/F3 cell lines expressing the various F-mutants had identical growth rates when deprived of IL-3.

Expression of TEL/PDGFBKR tyrosine to phenylalanine mutants in primary hematopoietic cells results in distinct phenotypes in mice. To confirm the findings with the TEL/PDGFBKR F-mutants in primary hematopoietic cells, murine BMT was performed.

### Table 1

Summary of survival analysis of mice transplanted with TEL/PDGFBKR and related mutants

<table>
<thead>
<tr>
<th>Construct</th>
<th>Affected/total (%)</th>
<th>Median survival (days)</th>
<th>Phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEL/PDGFBKR</td>
<td>39/39 (100)</td>
<td>31</td>
<td>Myeloproliferative</td>
</tr>
<tr>
<td>ΔPNT</td>
<td>0/5 (0)</td>
<td>NR</td>
<td>NED</td>
</tr>
<tr>
<td>K634R</td>
<td>0/6 (0)</td>
<td>NR</td>
<td>NED</td>
</tr>
<tr>
<td>F2</td>
<td>15/20 (75)</td>
<td>146</td>
<td>Lymphoma</td>
</tr>
<tr>
<td>F5</td>
<td>22/22 (100)</td>
<td>76</td>
<td>Myeloproliferative</td>
</tr>
<tr>
<td>F7</td>
<td>22/31 (71)</td>
<td>225</td>
<td>Lymphoma</td>
</tr>
<tr>
<td>F8</td>
<td>3/16 (19)</td>
<td>NR</td>
<td>Lymphoma</td>
</tr>
<tr>
<td>K634R</td>
<td>0/6 (0)</td>
<td>NR</td>
<td>NED</td>
</tr>
<tr>
<td>DPNTR</td>
<td>39/39 (100)</td>
<td>31</td>
<td>Myeloproliferative</td>
</tr>
</tbody>
</table>
| NR, not reached within 300-day follow-up period. NED, no evidence of disease.

humans. There was a marked expansion of maturing granulocytes and precursors within normal sites of hematopoiesis, the bone marrow and splenic red pulp, occasionally accompanied by splenic infarction (Figure 2b). The marrow also demonstrated increased collagen deposition, based on silver impregnation stains (data not shown). Extramedullary hematopoiesis was also present at abnormal sites, including the hepatic and pulmonary parenchyma and lymph nodes (Figure 2c and data not shown). There was no evidence of myeloproliferative disease in TEL/PDGFBKR transplanted mice.

Expression of TEL/PDGFBKR. Expression was confirmed in affected tissues of transplanted animals by RT-PCR and by GFP expression from appropriate vectors. In RT-PCR experiments (Figure 3a), RNA integrity was confirmed by amplification of wild-type TEL RNA, with RT-negatives and water controls. Because GFP is expressed from a single transcript containing TEL/PDGFBKR and an IRES/GFP cassette, GFP expression in intact cells, as assessed by fluorescent microscopy is an informative surrogate for expression of TEL/PDGFBKR. As shown in Figure 3b, there were high levels of GFP expression in hematopoietic cells.

Clonality of myeloproliferative disease. Southern blotting of genomic DNA isolated from transplanted animals using a neomycin probe confirmed proviral integration event thus yielded a unique band. The tumors in mice transplanted with TEL/PDGFBKR were oligo- or polyclonal, as evidenced by multiple bands in these lanes (Figure 3c).

Signal transduction pathways associated with PDGFBR activation are not required for the transformation of Ba/F3 cells by TEL/PDGFBKR. The native PDGFBR requires specific tyrosine residues for signaling through distinct transduction pathways (5). To determine the tyrosine residues required for the development of the myeloproliferative phenotype, we analyzed a series of TEL/PDGFBKR mutants containing tyrosine to phenylalanine point mutations designed to abrogate the binding of specific SH2 adapter signaling molecules (Figure 4). Control experiments showed that these mutations had no effect on PDGFBR kinase activity in the context of the TEL/PDGFBKR fusion (D.W. Sternberg and D.G. Gilliland, unpublished observation). Ba/F3 cell lines expressing each of these mutants were generated and assessed for their ability to grow in the absence of IL-3. Each of the F-mutants conferred IL-3–independent growth to Ba/F3 cells (Figure 5). Furthermore, stable Ba/F3 cell lines expressing the various F-mutants had identical growth rates when deprived of IL-3.

Expression of TEL/PDGFBKR tyrosine to phenylalanine mutants in primary hematopoietic cells results in distinct phenotypes in mice. To confirm the findings with the TEL/PDGFBKR F-mutants in primary hematopoietic cells, murine BMT was performed.

### Figure 4

Tyrosine to phenylalanine signaling mutants of TEL/PDGFBKR. The NH2-terminal TEL portion of the fusions, indicated by a shaded box, remains unchanged in the wild-type and mutants. Phosphotyrosines in the PDGFBR portion of the fusion are indicated by “Y” and are numbered according to the wild-type PDGFBR sequence. Mutants were generated with tyrosine to phenylalanine (F) substitutions at specific residues as indicated. The split kinase domain of PDGFBR is indicated by striped ovals.
using viral supernatants of equivalent titer, with the F2, F7, and F8 mutants that maintained normal white blood counts (data not shown) and did not develop myeloproliferative disease (Figure 7). Initially, these animals appeared to be unaffected by the transplanted tyrosine kinase fusions. However, after a latency of several months, these mice developed mediastinal tumors that expressed high levels of the mutant TEL/PDGFR as assessed by Western blot (Figure 7, and data not shown). The median survival of the F2 and F7 were 146 and 225 days, respectively, whereas the median survival of the F8 mice was not reached by 300 days after transplant (Figure 6).

**TEL/PDGFR mutants lacking PDGFβR juxtamembrane tyrosines 579/581 develop clonal T-cell lymphomas.** The mice transplanted with F2, F7, and F8 mutants developed a characteristic clinical syndrome consisting of labored breathing and exophthalmos after a latency of at least 14 weeks. Necropsy showed mediastinal masses that were frequently associated with pleural effusions (data not shown). Microscopic analysis revealed that these tumors invaded the chest wall, tracked along the bronchi, encased the lungs, and replaced the spleen and bone marrow (Figure 7, and data not shown).

Flow cytometry of cells isolated from the spleens of affected animals demonstrated an abnormal population with a B220−, CD3lo, Thy-1+, and CD4/CD8 double-positive immunophenotype, consistent with an immature T-cell phenotype (Figure 8). An identical immunophenotype was seen in mediastinal tumors and in bone marrow (data not shown).

**Proviral integration and gene rearrangement studies.** Mediastinal tumors from mice transplanted with the F2, F7, and F8 mice contained proviral DNA as assessed by Southern blot (Figure 9a). However, in contrast to the pattern of oligo- or polyclonality seen in animals with myeloproliferative disease, these clonality analyses revealed either a single or a double band, indicating that these were clonal tumors. This conclusion was confirmed by the gene rearrangement studies described below.

The T-cell origin of these tumors was confirmed by
Southern blot analysis of the TCR-β gene (Figure 9b). In all cases tested, the tumors demonstrated clonal rearrangement of the TCR-β locus. In 8 of 9 mice analyzed, there were 2 bands of equal intensity corresponding to rearrangement of both TCR-β alleles, consistent with monoclonal derivation. In one case, there were 4 bands, indicating the presence of at least 2 independent T-cell clones. The immunoglobulin heavy chain gene locus was not rearranged in these tumors (data not shown). The T-cell lymphomas associated with the F2, F7, and F8 mutants were readily transplantable into sublethally irradiated secondary recipients with as few as $10^4$ cells and also gave rise to mediastinal T-cell lymphomas (data not shown).

Discussion
We have demonstrated that expression of TEL/PDGF-βR in unfractionated bone marrow results in a myeloproliferative disease with features of the human disease CMML. Features of CMML that are recapitulated in the murine BMT model include leukocytosis with normal maturation and differentiation, splenomegaly, bone marrow fibrosis, and extramedullary hematopoiesis in multiple organs including spleen and liver. It has also recently been reported that expression of TEL/PDGF-βR under the control of the CD11b promoter in transgenic mice can cause a myeloproliferative phenotype (12).

The rapid onset of disease after BMT, and the polyclonal nature of the disease, favor the hypothesis that...
TEL/PDGFβR is both necessary and sufficient to cause this myeloproliferative phenotype. We cannot exclude the possibility that retroviral integration itself contributes to the myeloproliferative phenotype. However, this event would have to be both common enough to yield polyclonal disease and yet have no effect in animals transplanted with retrovirus containing inactive mutants of TEL/PDGFβR, an unlikely possibility.

TEL/PDGFβR is exclusively associated with CMML in humans (13, 14). Nonetheless, it was unexpected that TEL/PDGFβR would cause a myeloproliferative phenotype in the murine BMT model without histopathological evidence of lymphoid or other lineage involvement. First, the introduction of TEL/PDGFβR into primary hematopoietic cells via retroviral gene transfer allows for expression in multiple hematopoietic lineages, including lymphoid cells (15). Use of this murine BMT technique with the BCR/ABL fusion (16) or the TEL/JAK2 (17) tyrosine kinase fusion produces phenotypes consisting of tumors derived from multiple hematopoietic lineages. Second, we have previously reported that transgenic mice expressing TEL/PDGFβR under the control of the immunoglobulin promoter-enhancer EμP(17) develop B-cell lymphoblastic lymphomas, demonstrating that TEL/PDGFβR is capable of causing lymphoid tumors (11). However, transformation of lymphoid cells in EμP(17)-TEL/PDGFβR transgenic mice requires a relatively long latency of 2–4 months, and these tumors are clonal, indicating that additional genetic events are required for transformation of lymphoid cells (10). The lack of involvement of the lymphoid lineage after BMT is therefore probably because longer latency lymphoid disease in transplanted mice is masked by the development of a rapidly fatal myeloproliferative disease. Collectively, these data demonstrate the importance of the target cell in transformation by oncogenic fusion proteins, as recently reviewed by Westervelt and Ley (18).

Two additional chromosomal translocations associated with CMML, t(5;7)(q33;q11.2) and t(5;10)(q33;q11.2), have recently been cloned and also result in the fusion of the PDGFβR gene to the HIP1 and H4 genes, respectively (19, 20). TEL, HIP1, and H4 are unrelated proteins that each contribute a dimerization/oligomerization motif to the respective PDGFβR fusion. Taken together, these observations suggest that PDGFβR tyrosine kinase activation can be subserved by a spectrum of fusion partners using different dimerization motifs and that a critical event in the pathogenesis of CMML is constitutive activation of the PDGFβR kinase domain and its downstream targets.

The rapid onset of disease in transplanted mice enabled us to use the murine BMT as an assay to test the role of individual downstream signal transduction pathways in the development of CMML. In the Ba/F3 cell context, each of the tyrosine to phenylalanine mutants was capable of conferring IL-3-independent growth, and the growth rates of stable cell lines express-
ing each F-mutant were identical when the cell lines were grown in the absence of IL-3. However, there was a dramatic difference in phenotype of TEL/PDGFβR and the F5 mutants that conferred a myeloproliferative disease phenotype, and the F2, F7, and F8 mutants, which conferred a T-cell lymphoblastic lymphoma phenotype. Although the F8 mutant lacks the major SH2 interaction sites in the context of the native receptor, the F8 mutant remains constitutively phosphorylated on tyrosine (D.S. Sternberg and D.G. Gilliland, unpublished observation). Thus, other SH2 interaction sites may be functioning in this mutant. The difference in phenotype cannot be explained by differences in viral supernatant titers, which were equivalent (data not shown), or by differences in PDGFβR kinase activity in the context of the mutants, which was also equivalent. These findings suggest that mutational analysis of oncogenic proteins in hematopoietic cell lines must be interpreted with caution, and data should be corroborated in transformation assays of primary hematopoietic cells.

Our data indicate that the juxtamembrane tyrosine residues of the wild-type PDGFβR, 579/581, are critical for the development of myeloid disease in the BMT assay. The 579/581 tyrosines of the wild-type PDGFβR are required for the binding and activation of SRC family kinases (21), as well as activation of STAT family members by PDGFβR (22, 23). Activated SRC exerts its downstream effects in part through activation of MYC (24). TEL/PDGFβR has been shown to activate MYC (25), and dominant negative MYC inhibits growth of TEL/PDGFβR transformed cells (25). Thus, activation of MYC by SRC family members may play an important role in transformation of myeloid cells by TEL/PDGFβR.

STAT5 activation may also play an important role in transformation of hematopoietic cells and is known to be activated by a spectrum of tyrosine kinase fusions associated with human leukemias, including BCR/ABL (26), TEL/ABL (27), TEL/JAK2 (17), HIP1/PDGFβR (28), and TEL/PDGFβR (D. W. Sternberg and D. G. Gilliland, unpublished observation). Furthermore, STAT5 is required for TEL/JAK2-mediated myeloproliferation in a murine BMT model (29). Thus, activation of STAT5 by residues Y579/S81 may also be important in transformation of myeloid cells by TEL/PDGFβR.

Mutations affecting residues besides 579/581 incrementally prolonged the latency of lymphoid disease (Figure 6 and Table 1). The graded decrement in oncogenicity cannot be attributed to variations in PDGFβR kinase activity or to differences in viral supernatant titer. However, a similar mechanism of action for native PDGFβR function, invoking signal strength, has recently been proposed. Fambrough et al. used oligonucleotide microarrays to examine the immediate early genes induced by PDGFβR and a similar series of tyrosine to phenylalanine mutants as those used in this report in the context of the native PDGFβR (30). The overall levels of expression of these target genes were diminished with progressive tyrosine to phenylalanine substitutions, and it was suggested that the various signaling pathways activated by PDGFβR converge upon a common set of downstream targets. The data from the murine BMT assay of TEL/PDGFβR tyrosine to phenylalanine mutants would be consistent with this hypothesis.

**Figure 9**
Assessment of proviral integration and TCR-β gene rearrangements. (a) As in Figure 3c, Southern blot analysis of tumors from transplanted animals demonstrates the presence of provirus. A human TEL probe that did not cross-hybridize with the endogenous murine TEL was used as a virus-specific probe. Neomycin vectors yield a 5-kb band (filled arrowhead), and GFP-containing vectors yield a 4-kb band (open arrowhead). (b) Genomic DNA isolated from F2, F7, and F8 mediastinal tumors subjected to Southern blot analysis using a TCR-β probe. Rearrangement of the TCR-β locus in each case proves the T-cell identity of these tumors. Clonality is demonstrated by the presence of 2 unique TCR-β alleles per case and is seen in the majority of tumors. The tumor from mouse 13.17 shows 4 bands, suggesting a biclonal tumor in this case. Contamination of tumor samples with stromal cells results in the presence of the unrearranged germline band (arrowhead).
Acknowledgments
The authors thank M. Ryan for secretarial and administrative assistance; E. Lander and K. Weilbaecher for critical review of the manuscript; and members of the Gilliland lab for valuable discussion. This research was supported in part by a grant from the Leukemia Society of America (5461-98 to M.H. Tomasson) and grants from the National Institutes of Health (K08 CA81197-01 to M.H. Tomasson; P01CA66996-01 and P01K50654 to D.G. Gilliland; R01 CA57593 to R.A. Van Etten; and K08 HL03310 to R.L. Ilaria.) D.G. Gilliland is an Associate Investigator in the Howard Hughes Medical Institute.